Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24901418 | 0.84 | MMP2 (0.43) | MMP2MMP1MMP9MMP12BDKRB1 | |
| SCHEMBL24901419 | 0.81 | MMP1 (0.33) | MMP2MMP1MMP9MMP12MAOB | |
| SCHEMBL24901409 | 0.81 | CA1 (0.32) | MMP2MMP1MMP9MMP12MAOB | |
| SCHEMBL24945950 | 0.77 | MAOB (0.49) | MMP2MMP1MMP9MMP12MAOB | |
| SCHEMBL17552780 | 0.77 | RIPK1 (0.45) | MMP2MMP1MMP9MMP12MAOB | |
| SCHEMBL24901129 | 0.77 | MMP1 (0.39) | MMP2MMP1MMP9MMP12BDKRB1 | |
| SCHEMBL24945949 | 0.77 | MMP2 (0.48) | MMP2MMP1MMP9MMP12MAOB | |
| SCHEMBL24142266 | 0.76 | MMP1 (0.37) | MMP2MMP1MMP9MMP12 | |
| SCHEMBL24142279 | 0.76 | ALDH1A1 (0.47) | MMP2MMP1MMP9MMP12MAOB | |
| SCHEMBL24901359 | 0.75 | PTGER1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023593-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230019681-A1 | POSITIVE RESIST MATERIAL AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023593-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | HNRNPU, EWSR1, HNRNPR | MMP2 4588/4885MMP1 4189/4885MMP9 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.